4.3 Article

Impact of Completeness of Revascularization on Long-Term Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D)

期刊

CIRCULATION-CARDIOVASCULAR INTERVENTIONS
卷 5, 期 2, 页码 166-173

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/CIRCINTERVENTIONS.111.963512

关键词

coronary artery disease; type 2 diabetes mellitus; coronary artery bypass grafting; percutaneous coronary intervention

资金

  1. National Heart, Lung, and Blood Institute
  2. National Institute of Diabetes and Digestive and Kidney Diseases [U01 HL061744, U01 HL061746, U01 HL061748, U01 HL063804]
  3. GlaxoSmithKline, Collegeville, PA
  4. Bristol-Myers Squibb Medical Imaging, Inc, North Billerica, MA
  5. Astellas Pharma US, Inc, Deerfield, IL
  6. Merck & Co, Inc, Whitehouse Station, NJ
  7. Abbott Laboratories, Inc, Abbott Park, IL
  8. Pfizer, Inc, New York, NY
  9. Abbott Laboratories Ltd, MediSense Products, Mississauga, Canada
  10. Bayer Diagnostics, Tarrytown, NY
  11. Becton, Dickinson and Company, Franklin Lakes, NJ
  12. J.R. Carlson Labs, Arlington Heights, IL
  13. Centocor, Inc, Malvern, PA
  14. Eli Lilly and Company, Indianapolis, IN
  15. LipoScience, Inc, Raleigh, NC
  16. Merck Sante, Lyon, France
  17. Novartis Pharmaceuticals Corporation, East Hanover, NJ
  18. Novo Nordisk, Inc, Princeton, NJ

向作者/读者索取更多资源

Background-Patients with diabetes have more extensive coronary disease than those without diabetes, resulting in more challenging percutaneous coronary intervention or surgical (coronary artery bypass graft) revascularization and more residual jeopardized myocardium. The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial provided an opportunity to examine the long-term clinical impact of completeness of revascularization in patients with diabetes. Methods and Results-This is a post hoc, nonrandomized analysis of the completeness of revascularization in 751 patients who were randomly assigned to early revascularization, of whom 264 underwent coronary artery bypass graft surgery and 487 underwent percutaneous coronary intervention. The completeness of revascularization was determined by the residual postprocedure myocardial jeopardy index (RMJI). RMJI is a ratio of the number of myocardial territories supplied by a significantly diseased epicardial coronary artery or branch that was not successfully revascularized, divided by the total number of myocardial territories. Mean follow-up for mortality was 5.3 years. Complete revascularization (RMJI=0) was achieved in 37.9% of patients, mildly incomplete revascularization (RMJI > 0 <= 33) in 46.6%, and moderately to severely incomplete revascularization (RMJI > 33) in 15.4%. Adjusted event-free survival was higher in patients with more complete revascularization (hazard ratio, 1.14; P=0.0018). Conclusions-Patients with type 2 diabetes mellitus and less complete revascularization had more long-term cardiovascular events.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据